News Archive

January 29, 2024
Carmot Therapeutics Announces Completion of Acquisition by Roche
December 04, 2023
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
November 15, 2023
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes
October 15, 2023
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®
October 10, 2023
Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996
September 26, 2023
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
July 19, 2023
Carmot Therapeutics Appoints Charles W. Newton to Board of Directors
June 23, 2023
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
June 06, 2023
Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer
May 25, 2023
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes
May 23, 2023
Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
January 05, 2023
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
Making what matters possible.

Carmot Therapeutics Inc.
A Member of the Roche Group
740 Heinz Avenue
Berkeley, CA 94710
[email protected]

©2024 Carmot Therapeutics, Inc. All Rights Reserved.
Privacy Policy Terms of Use Site Design: Monderer Design